IPO - Profile


BriaCell is an immuno-oncology biotechnology company with a strong focus on cancer immunotherapy. Immunotherapies have come to the forefront in the fight against cancer. They harness the body’s own immune system to recognize and destroy cancer cells. BriaCell owns the US patent to SV-BR-1-GM (Bria-IMT™), a whole-cell targeted immunotherapy for cancer (U.S. Patent No. 7,674,456), as well as patents related to PKCδ inhibitors (U.S. Patent Nos. 9,364,460 and 9,572,793).

The Company is currently advancing its targeted immunotherapy program by prioritizing a Phase I/IIa clinical trial with Bria-IMT™ in combination with an More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$4.25 5,880,000 Positive High 43.29%

Offering Team

  • Legal counsel
  • Sichenzia Ross Ference Kesner LLP
  • Auditors

Deal Highlights

Deal Tracker

IPO Dates

Filing 23 Feb, 2021

Offer 24 Feb, 2021

Look Ahead

Lock Up Expiry Aug 24, 2021

IPO Terms

Offer Price $4.25
Offer Size 5M

Market Sentiments

Stock Price